Lipoprotein-associated phospholipase A2: A potential new risk factor for coronary artery disease and a therapeutic target

Current Opinion in Pharmacology

Volumn 1, Issue 2, 2001, Pages 121-125

  Macphee, Colin H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Atherosclerosis; Coronary artery disease; Drug Discovery; Lipoprotein associated phospholipase A2; Macrophages; Molecular Medicine; Monocytes; Pharmacology; Phospholipase A2; Platelet activating factor acetylhydrolase; WOSCOPS

Indexed keywords

BIOLOGICAL MARKER; ENZYME INHIBITOR; FATTY ACID; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A(2); LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2); LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; ENZYMOLOGY; HUMAN; INFECTION; INFLAMMATION; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY; REVIEW; RISK FACTOR;

ANIMAL; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; ENZYME INHIBITORS; FATTY ACIDS, NONESTERIFIED; HUMAN; INFECTION; INFLAMMATION; LIPOPROTEINS, LDL; LYSOPHOSPHATIDYLCHOLINES; OXIDATION-REDUCTION; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; RISK FACTORS;

EID: 0035321963     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00024-8     Document Type: Review

References (31)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 340:1999;115-126. A delightfully scripted overview of the inflammatory processes that constitute atherogenesis.
2. Chisolm G.M., Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med. 28:2000;1815-1826. Review providing a balanced perspective on the strengths and weaknesses of the oxidative modification hypothesis of atherogenesis.
3. Heinecke J.W. Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. FASEB J. 13:1999;1113-1120.
4. Khovidhunkit W., Memon R.A., Feingold K.R., Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 181:2000;S462-S472. Currently a rather unique article that does a good job in pulling together data linking chronic infections with atherosclerosis. It describes the underlying enzymology responsible for the pro-atherogenic changes in lipoprotein metabolism that occur during infection.
5. Jessup W., Kritharides L. Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol. 11:2000;473-481.
6. Davies M.J. The pathophysiology of acute coronary syndromes. Heart. 83:2000;361-366. A comprehensive description of the vulnerable plaque with some thoughts on what makes it prone to fissure.
7. Libby P., Ridker P.M. Novel inflammatory markers of coronary risk. Circulation. 100:1999;1148-1150. Very good mini-review on plasma markers of CHD that appear to reflect an inflammatory response.
8. Tracy R.P. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 10:1999;435-441.
9. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 340:1999;448-454. A complete description of acute-phase responses whether behavioural, biochemical or nutritional.
10. 2 predict coronary events in patients with coronary artery disease. Circulation. 100:1999;1280-1284.
11. 2 levels to be an independent and strong predictor of clinical events not influenced by other inflammatory markers or even LDL.
12. Asano K., Okamoto S., Fukunaga K., Shiomi T., Mori T., Iwata M., Ikeda Y., Yamaguchi K. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 261:1999;511-514.
13. Nakajima K., Murakami M., Yanoshita R., Samejima Y., Karasawa K., Setaka M., Nojima S., Kudo I. Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating factor. J Biol Chem. 272:1997;19708-19713.
14. Laine P., Kaartinen M., Penttila A., Panula P., Paavonen T., Kovanen P.T. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation. 99:1999;361-369.
15. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 19:1999;2909-2917.
16. 2 during LDL oxidation are, like lyso-PC, chemoattractants for human monocytes.
17. 2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 150:2000;413-419.
18. Nielson L.B. Atherogenecity of lipoprotein(a) and oxidised low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis. 143:1999;229-243.
19. Rikitake Y., Kawashima S., Yamashita T., Ueyama T., Ishido S., Hotta H., Hirata K., Yokoyama M. Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. Arterioscler Thromb Vasc Biol. 20:2000;1006-1012.
20. Kugiyama K., Sugiyama S., Ogata N., Oka H., Doi H., Ota Y., Yasue H. Burst production of superoxide anion in human endothelial cells by lysophosphatidylcholine. Atherosclerosis. 143:1999;201-204.
21. Memon R.A., Fuller J., Moser A.H., Feingold K.R., Grunfeld C. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol. 46:1999;R94-R103.
22. Howard K.M., Olson M.S. The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. J Biol Chem. 275:2000;19891-19896.
23. Memon R.A., Staprans I., Noor M., Holleran W.M., Uchida Y., Moser A.H., Feingold K.R., Grunfeld C. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol. 20:2000;1536-1542.
24. 2 by monocyclic β-lactams. Burst kinetics and the effect of stereochemistry. Biochemistry. 37:1998;10087-10093.
25. 2 reduced atherosclerosis in a relevant animal model of disease without provoking any untoward responses.
26. Prescott S.M., Zimmerman G.A., Stafforini D.M., McIntyre T.M. Platelet-activating factor and related lipid mediators. Annu Rev Biochem. 69:2000;419-445. A comprehensive review that focuses solely on emphasising the potential of PAF and related lipids in the pathophysiology of diseases, including atherosclerosis.
27. Yamada Y., Ichihara S., Fujimura T., Yokota M. Identification of the G(994)-T missense mutation in exon nine of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism. 47:1998;177-181.
28. Yamada Y., Yoshida H., Ichihara S., Imaizumi T., Satoh K., Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis. 150:2000;209-216.
29. Yoshida H., Imaizumi T., Fujimoto K., Itaya H., Hiramoto M., Yoshimizu N., Fukushi K., Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension. Thromb Haemost. 80:1998;372-375.
30. Stafforini D.M., Numao T., Tsodikov A., Vaitkus D., Fukuda T., Watanabe N., Fueki N., McIntyre T.M., Zimmerman G.A., Makino S., et al. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest. 103:1999;989-997.
31. Satoh N., Asano K., Naoki K., Fukunaga K., Iwata M., Kanazawa M., Yamaguchi K. Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma. Am J Respir Crit Care Med. 159:1999;974-979.